2019 Chemotherapy Vaccines 
Hospital Pharmacy Europe
OCTOBER 2, 2024
Pharmacist Dr João Gonçalves PhD considers the real-world evidence of a recent study demonstrating the feasibility and efficacy of a personalised peptide vaccine for glioblastoma – one of the most malignant primary brain tumours in adults.
pharmaphorum
SEPTEMBER 8, 2020
In England for instance, the introduction of a biosimilar to prevent neutropenia in patients undergoing chemotherapy, resulted in a number of Strategic Health Authorities reassessing their guidance relating to this medicine. Published 8 March 2019. Published 25 November 2019. Published 17 September 2018. Available from: [link].
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
DECEMBER 12, 2023
IPH5201 is being investigated in a Phase II trial, MATISSE, in combination with durvalumab (anti-PD-L1) and chemotherapy, in patients with resectable early-stage NSCLC. Innate Pharma also developing IPH5201 in collaboration with AstraZeneca. percent, reaching even 57.1 percent in the skin.
pharmaphorum
APRIL 7, 2021
Under the leadership of CEO Jan van de Winkel it has gone from financially precarious position following the stock market crash in the late noughties, to the darling of the Nasdaq with a US IPO of more than $500 million in 2019. There’s potential for combination drugs, paving the way for less toxic chemotherapy-free cancer drugs.
Pharmaceutical Technology
MARCH 2, 2023
Keytruda is indicated in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. It is also indicated for the treatment of metastatic transitional (urothelial) tract cancer and gastric cancer.
pharmaphorum
AUGUST 22, 2022
Chemotherapy, the current standard of care for cancer treatment, can be harmful to both the cancer cells and the body’s healthy cells. ” Moderna has also created a personalised cancer vaccine, a similar idea where the vaccine is built against the specific cancer one has in the body. ” About the interviewee.
The Checkup by Singlecare
NOVEMBER 13, 2023
According to the CDC , treatment includes surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these treatments. To help decrease the risk of shingles, Shingrix vaccine is FDA-approved for adults 50 and older. It is a two-vaccine series and significantly decreases the risk of a shingles outbreak.
Expert insights. Personalized for you.
52 
Let's personalize your content